Lexeo Therapeutics, Inc. (LXEO) vs Pyxis Oncology, Inc. (PYXS)

Lexeo Therapeutics, Inc. and Pyxis Oncology, Inc. are both Biotechnology companies. Lexeo Therapeutics, Inc. and Pyxis Oncology, Inc. are of similar size ($226.6M and $215.3M). Across the 10 metrics below, Lexeo Therapeutics, Inc. leads on 7 and Pyxis Oncology, Inc. on 3.

Valuation

Metric LXEO PYXS Biotechnology median
P/E n/m n/m 8.42
P/S n/m n/m 10.01
P/B 1.01 10.07 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales n/m n/m 9.41
Earnings yield (41.67%) (78.33%) (31.85%)
Free cash flow yield (37.54%) (58.96%) (24.58%)

Profitability

Metric LXEO PYXS Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (46.76%) (179.10%) (56.36%)
Return on assets (40.50%) (99.62%) (48.04%)
Return on invested capital (253.48%) 0.00% 0.00%

Growth

Metric LXEO PYXS Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 39.81% 3.03% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LXEO PYXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.89 1.34 4.72
Net debt to EBITDA 1.67 0.82 0.96

Dividend

Metric LXEO PYXS Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric LXEO PYXS Biotechnology median
Market cap 226.56m 215.25m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack